Navigation Links
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Date:5/13/2008

said Paul LaViolette, Chief Operating Officer of Boston Scientific. "With the anticipated FDA approval of the XIENCE V (PROMUS) Stent and the launch of the TAXUS Liberte Stent this year, we are excited to offer physicians and their patients two drugs on two highly deliverable platforms."

The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. The PROMUS and TAXUS Liberte(R) Stents have received CE Mark approval and are distributed in most European countries and other international markets. The XIENCE V (PROMUS) Stent is an investigational device in the U.S. and not yet approved for sale. It is currently under FDA review with an anticipated U.S. launch in 2008.

SPIRIT III is sponsored by Abbott. TAXUS, TAXUS Express2, Express, Liberte and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories Group of Companies.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance and competitive offering
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Exelixis Announces First Quarter 2008 Financial Results
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... Switzerland (PRWEB) , ... September 01, 2015 , ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring ... presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, ...
(Date:9/1/2015)... Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... and makes the massage robots more effective and humanlike than ever before. With the ... chairs, the Ogawa Refresh and the Ogawa Active SuperTrac. , As in its ...
(Date:9/1/2015)... NV (PRWEB) , ... September 01, 2015 , ... ... or Self-Directed Care is, how to access caregivers and what to look for ... valuable and pertinent information. , Founded in 2006 in Canoga Park, CA by ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... dating men and pick-up artists about their experiences of female beauty, women’s emotions, ... concerns, including penis issues, as well as their relationships with other men, documenting ...
(Date:9/1/2015)... Chicago, IL (PRWEB) , ... September 01, 2015 ... ... Traumeel™ and Zeel™, has recently sponsored an educational workshop for physician assistants (PAs) ... I.A. Injections of Traumeel™ and Zeel™” was held by Dr. Erick Salado, an ...
Breaking Medicine News(10 mins):Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... Cancer Research Insitiute, UK suggests that women on tamoxifen have ... They report on a large scale trial of tamoxifen to ... to 65 years, from the UK, Australia, New Zealand and ... the women were considered as being at increased risk of ...
... effective delivery of drugs for a number of conditions. According to ... with the use of nasal sprays to treat allergies such as ... of delivering a drug, because it gets into the bloodstream fast ... fact, act quicker than the corresponding pill. Nasal sprays are already ...
... can control a stressful situation makes it easier on ... is potentially damaging to health because it increases blood ... responses may accumulate to increase the risk of heart ... stress is moderated by many psychological factors, such as ...
... that reduces the level of copper in the blood ... animals. Wilson's disease is a rare disorder where patients ... bodies. Researchers at the University of Texas, through research ... as tetrathiomolybdate (TM) that could fight cancer by lowering ...
... could be used to treat heart and lung disease. ... experiment in healthy young men,// the results of which ... and lung disease. ,They report that the ... hypertension (caused by conditions such as heart valve disease, ...
... in the American Journal of Clinical Nutrition it was observed ... the build up of plaque in the arteries that can ... can protect against the formation of plaque in the arteries. ... diagnosed with heart disease or who had suffered a heart ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: